Nymox Pharmaceutical (NYMX) Receiving Favorable Media Coverage, Analysis Finds

News stories about Nymox Pharmaceutical (NASDAQ:NYMX) have trended positive recently, according to Accern Sentiment. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nymox Pharmaceutical earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.3131835332854 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Nymox Pharmaceutical (NASDAQ:NYMX) traded up $0.24 on Thursday, reaching $3.63. The company had a trading volume of 129,100 shares, compared to its average volume of 159,760. Nymox Pharmaceutical has a 52 week low of $2.67 and a 52 week high of $5.10. The company has a debt-to-equity ratio of 61.64, a quick ratio of 1.42 and a current ratio of 1.44.

Separately, ValuEngine cut Nymox Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th.

TRADEMARK VIOLATION WARNING: This article was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.com-unik.info/2017/12/14/nymox-pharmaceutical-nymx-receiving-favorable-media-coverage-analysis-finds.html.

About Nymox Pharmaceutical

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

What are top analysts saying about Nymox Pharmaceutical? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nymox Pharmaceutical and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit